A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction (LYNK-003)
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital
Study ID
Protocol Number: 19-6102
More information available at ClinicalTrials.gov: NCT04456699
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers